Skip to main content
Premium Trial:

Request an Annual Quote

NIST to Spend $6.3M to Improve Microarray Research; Seeks Vendor, User Input

NEW YORK, Nov. 11 (GenomeWeb News) - The National Institute of Standards and Technology will spend $6.25 million to develop a program aimed at identifying and addressing challenges in gene-expression measurement, validation and quality control, NIST said yesterday.

 

Over the next 5 years, the group, called the Metrology for Gene Expression Program, will try to "improve the quality, reliability and comparability of gene expression measurements with microarrays," the agency said in a statement.

 

To these ends, the group will work with microarray tool vendors and users in order to "evaluate sources of error and variability in measurement." From this, the groups hopes to "develop reference data, reference materials and measurement methods to enable quality assurance for the chemistry, detection methods and information processing used in microarray analysis."

 

To illustrate one challenge in standardizing gene-expression data, the NIST said that one experiment using three different microarray platforms to measure the same sample found that "under the most stringent criteria the three agreed on only four out of 275 genes identified."

 

"Enormous quantities of gene-sequence data are pouring out of labs thanks to dramatic gains in DNA sequencing technology, but that's only a start," NIST said. "The real question is how genetic information translates into biological activity."

 

The External RNA Control Consortium, a group of almost 50 organizations from industry, academic labs, federal agencies and other key stakeholders, helped "inspire" the group, it said.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.